VIDEO: Expert discusses data from Lung-MAP sub-study
Click Here to Manage Email Alerts
Roy Herbst, MD, PhD, discussed updated toxicity data from the Lung-MAP non-matched sub-study S1800A presented at the virtual ASCO Annual Meeting.
“This abstract basically describes the trial and some of the toxicity information,” he said.
According to the study, ramucirumab plus pembrolizumab was “generally well tolerated” among patients with advanced non-small cell lung cancer who previously were treated with a checkpoint inhibitor.
Herbst, a study co-author and associate cancer center director for translational research at Yale Cancer Center, was also involved in the phase 1 trial.
Collapse
Healio Interview; Reckamp KL, et al. Abstract 9075. Scheduled for presentation at: ASCO Annual Meeting (virtual meeting); June 4-8, 2021.
Read more about
Click Here to Manage Email Alerts